• Company’s investigational drug is being tested for the first time ever on humans in an FDA-approved study
• In phase 1 studies, IGC-AD1 shows potential to safely reduce debilitating symptoms
• IGC is actively building a portfolio of both cannabis-based and manufactured molecules that can address multiple areas of unmet medical needs

In groundbreaking work that establishes its commitment to being a pioneer in the treatment of Alzheimer’s disease, India Globalization Capital (NYSE American: IGC) is developing a cannabis-based investigational drug that is being tested for the first time ever on humans in an FDA-approved study (https://ibn.fm/qsc42). The company is developing its proprietary treatment, IGC-AD1, hoping to provide relief to the 55 million people worldwide struggling with agitation in dementia that results from Alzheimer’s.

IGC is focused on revolutionizing the treatment of Alzheimer’s with its game-changing treatment. In phase 1 studies, IGC-AD1 shows potential to safely reduce the debilitating symptoms that impact millions of Alzheimer’s patients and their caregivers. Featuring a low dose of THC, the treatment is the first natural cannabis-based investigational drug being tested in human FDA trials to treat Alzheimer’s patients; it provides medical benefits without psychoactive effects. “As millions of Alzheimer’s patients continue to suffer from agitation, anxiety, and depression, phase 2 clinical trials bring hope for a treatment,” the company reports.

In addition to IGC-AD1, IGC is actively building a portfolio of both cannabis-based and manufactured molecules that can address multiple areas of unmet medical needs (https://ibn.fm/0Q0iY). The company’s TGR-63 product is being studied for its potential to decrease Alzheimer’s markers, including plaque buildup, while also decreasing cognitive decline and improving memory. The company also has undisclosed molecules involved in exploratory activities.

With no current FDA-approved drugs to treat in Alzheimer’s patients, the company clearly has found a place where it can establish a foothold. In fact, last year less than 7% of drugs in clinical trials were focused on treating neuropsychiatric symptoms of Alzheimer’s. The time has clearly come for IGC. “What we do is important,” the company states. “With no known cure, our formulations have the potential to change lives.”

IGC develops advanced cannabinoid-based formulations for treating diseases, including but not limited to Alzheimer’s disease, Parkinson’s disease, chronic pain, and even pet seizures. The company sells various brands of CBD-based consumer products, including Holief, which includes gummies and pain relief creams for women experiencing premenstrual syndrome and dysmenorrhea (period cramps), and Sunday Seltzer, which includes a CBD-infused energy beverage. The company operates facilities in the United States under Good Manufacturing Practices.

For more information, visit the company’s website at www.IGCPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to IGC are available in the company’s newsroom at https://ibn.fm/IGC

• In a recent exclusive interview with Benzinga, Brian Haugli, SideChannel’s CEO, highlighted the looming cybersecurity issues threatening the cannabis industry, noting the vulnerabilities and glaring loopholes that could be exploited by individuals online with ill intent
• He emphasized the importance of addressing the human angle to cybersecurity, in addition to understanding that the sector has the same susceptibilities as the traditional agricultural sector
• This interview echoed SideChannel’s stand on matters of cybersecurity, as reflected in its annual meeting of stockholders held on February 15, 2023
• During the meeting, Deborah MacConnel was elected as chairperson, a welcome addition that also saw Anthony Ambrose and Kevin Powers join its board

In a recent exclusive interview with Benzinga, SideChannel (OTCQB: SDCH) CEO Brian Haugli laid bare the looming cybersecurity issues threatening the cannabis industry. Of note was his focus on the complacency of players in this sector, with many downplaying cybersecurity threats with the pretext that “no one would hack a weed company” (https://ibn.fm/NU36F).

As a company on a mission to make cybersecurity simple and accessible, based on the belief that small and mid-sized organizations deserve the expertise of an experienced Chief Information Security Officer (“CISO”), SideChannel is helping demystify issues surrounding cybersecurity across various industries. By making cybersecurity services more accessible, particularly to small and medium-sized businesses, the company is helping to keep businesses operational, intellectual properties secure, and workers protected from people online with ill intent.

Mr. Haugli noted that with the move toward online processing of payments, scheduling, and making payments, businesses within the cannabis space are exposing themselves to the same risks as those in other industries. The mere association with the cannabis space does not exclude them from the cybersecurity risks often associated with other sectors, especially in retail. In addition, given that the cannabis industry uses the same systems and has the same vulnerabilities as the traditional agricultural sector, players in this space ought to take cybersecurity much more seriously.

“People need to look at where they are in the cannabis supply chain, whether they’re growing, distributing, manufacturing, or selling cannabis products, and take the steps to address different risks,” Haugli noted.

In addition to having the appropriate cybersecurity infrastructure, Haugli emphasized the importance of addressing the human angle to cybersecurity and having a corporate culture that bolsters online safety. He highlighted SideChannel’s “focus on the people who do the operations and are the largest attack surface,” noting the importance of employee training for every position, safety training, and fire drills, among others.

“Companies are fine locking the front doors and hiring a security guard at their building, but sometimes they won’t patch or secure the computer systems or the cloud systems that hold their intellectual property,” Haugli noted.

“Nobody is going to physically steal the intellectual property of a cannabis company. It’s a lot easier to go through the system than through a wall,” he added.

This Benzinga interview echoed SideChannel’s stand on cybersecurity matters, as reflected in its annual meeting of stockholders on February 15, 2023. On the Investor Day broadcast, live-streamed on the same day, the company touched on the factors underpinning the growing demand for its cybersecurity program leadership and its focus on revenue relationships, evidenced by its trailing 12-month revenue.

“We appreciate the stockholder approval of our annual meeting proposals,” Haugli noted.

“We are committed to increasing direct engagement with our stockholders and were pleased with the participation at our investor day,” he added (https://ibn.fm/TuLig).

Haugli also noted SideChannel’s team’s commitment to delivering meaningful leadership to its clients, emphasizing why he wanted stockholders to understand why mid-market companies appreciated what the company does and why cybersecurity professionals love being on the SideChannel team.

During the stockholders’ meeting, Deborah MacConnel was elected chairperson, replacing Tom Wilkinson. This welcome addition also saw Anthony Ambrose and Kevin Powers join the board of directors. MacConnel will lend her knowledge and expertise from years of experience working in technology and software. She started at Adobe and just recently retired from IBM, where she was head of global sales teams and was responsible for transforming IBM’s internal processes in human resources.

“SideChannel is doing something special,” MacConnel noted.

“They are focused on solving a significant challenge for mid-market companies, and I look forward to working with the other members of the board to support and monitor SideChannel’s progress,” she added (https://ibn.fm/s97rF).

Haugli was optimistic about MacConnel’s appointment, noting that she would influence SideChannel’s go-to-market strategies and culture.

A replay of SideChannel’s Investor Day is available at https://ibn.fm/Gh0KT.

For more information, visit the company’s website at www.SideChannel.com.

NOTE TO INVESTORS: The latest news and updates relating to SDCH are available in the company’s newsroom at https://ibn.fm/SDCH

• During interview, Vajdic recounts first steps of journey in the United States
• CEO points to key lessons he learned that helped him found HeartBeam
• The company has developed the first and only 3D-vector 12-lead electrocardiogram (“ECG”) platform for heart attack detection anytime, anywhere

Growing up in Yugoslavia (now Serbia) as the only child of a well-known surgeon, HeartBeam (NASDAQ: BEAT) CEO and founder Branislav Vajdic, PhD, felt some pressure to study medicine and follow in his father’s footsteps. One day, at his father’s insistence, Vajdic observed a surgery — and fainted the moment he saw the first drop of blood. While that experience confirmed to Vajdic that medicine was not for him, decades later he is making his mark in the field of the detection and treatment of heart attacks.

“I was always fascinated with electronics; that was clearly my path,” said Vajdic during a recent “Authority Magazine” interview with David Leichner, part of an interview series focused on technology companies working to make a positive social impact (https://ibn.fm/rujH4). “As a junior in college, I spent a summer in the United States driving a truck and selling ice cream. I returned home, but in my mind, it was clear that I wanted to return to the U.S.

“And I did,” continued Vajdic. “Twenty-four hours after graduating with my bachelor’s degree in electrical engineering, I was on a plane to Minnesota to pursue my graduate studies.” During the interview, Vajdic recounted the steps of his journey in the United States, which included earning a doctorate degree in electrical engineering and being hired by Intel Corporation, where he was part of a small team that developed Intel’s first prototype for Flash memory.

Despite the landmark technology, the project was “put on the shelf” when market research showed that demand for Flash memory was small. Fortunately, almost a year later, Intel CEO Andy Grove restarted the Flash memory project, and the tech became an integral part of digital videos and photography, cell phones, and numerous electronics. Vajdic learned an invaluable lesson: Inertia is the biggest enemy of innovation.

That was only one lesson Vajdic shared during the interview; others included leadership by example, risk as an integral part of progress, and, if you believe in something, going all the way. Those lessons have been key as Vajdic founded a cardiac technology company called HeartBeam.

“At HeartBeam, we are addressing the need to determine if someone who is experiencing signs of a heart attack at home, work, or any place outside of a medical setting is actually experiencing one,” said Vajdic, who lost his own father to a heart attack. “It’s a huge issue. On average, most people wait over three hours before seeking care.

“Why? It is human nature to want to believe that the symptoms will go away, and that chest pain may be due to a pulled muscle or indigestion,” he continued. “Add to that a typically high health insurance deductible for an ER visit and at least a few hours of lost time, and you start to understand why the delay is so significant. That wait time means that the mortality rate goes up by some 40%.”

HeartBeam is developing the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere. By applying a suite of proprietary algorithms to simplify vector electrocardiography (“VECG”), the HeartBeam platform will enable patients and their clinicians to determine quickly and easily if symptoms are due to a heart attack so care can be expedited if required.

HeartBeam has two patented products in development. HeartBeam AIMI(TM) is software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to identify a heart attack more accurately. HeartBeam AIMIGo(TM) is the first and only credit-card-sized, 12-lead output ECG device coupled with a smartphone app and cloud-based diagnostic software system to facilitate remote heart-attack detection. HeartBeam AIMI and AIMIGo have not yet been cleared by the U.S. Food and Drug Administration (“FDA”) for marketing in the United States or other geographies.

For more information, visit the company’s website at www.HeartBeam.com.

NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

Professionals, influencers, solution providers, businesses, and executives of the pharma, biotech, medical device and other healthcare systems are invited to attend the 10th Advancing Women’s Leadership In Pharma & Healthcare conference being held from March 15-17, 2023 as a physical as well as an online live streaming event.

The event is hosted by Dynamic Global Events (“DGE”), a Life Science leader in organizing b2b events. The global event company caters to the dynamic informational and networking needs of the Pharmaceutical, Biotechnology, Healthcare, Medical Devices, and allied industries.

Industry Leaders of the healthcare and pharma sectors will discuss insights on winning business strategies for aspiring women professionals. These conferences are vital as more women professionals are becoming integral and senior parts of the healthcare workplace. Women entrepreneurs holding top posts in several healthcare and pharma companies will grace the occasion to share their experiences and offer valuable advice to the current women leaders in the industry.

Women are making it to top positions within organizations while crossing all barriers and facing challenges. They are equipped with phenomenal leadership skills that can take them to top company positions. This program aims to spread awareness and inspire the attendees to empower women leaders and close the gender disparity gap.

Case studies and life journeys shared by women entrepreneurs will serve as building blocks to motivate and aspire women professionals who are emerging to take up leadership roles in this landscape.  Women professionals possess the requisite leadership skills to lead companies, and this DGE Summit offers a great enhancing forum to inspire and embrace the role of women leaders in the workplace.

Women entrepreneurs will learn how to define parameters and say “No” without losing promotions and opportunities. Women can attain knowledge on how to perform the role of a multi-generational leader and make better connections and networking for career growth. Experts will also discuss why women hesitate from senior leadership roles and offer tips for the same.

The event is also a live-streaming program so attendees who cannot physically attend the conference can leverage the online facility and join the event.

To learn more, please visit https://ibn.fm/bAFVs.

• Freight Technologies, a technology company developing solutions to optimize and automate the supply chain process, has developed a B2B cross-border shipping freight matching platform through its subsidiary Freight App Inc. (“Fr8App”)
• The freight matching platform, known as Fr8App, supports several solutions, including Fr8Fleet, which enables shippers to secure freight capacity over time rather than on a trip-by-trip basis
• Fr8Fleet solves multiple problems faced by carriers and shippers, and has gained traction since its release in 2022
• Most recently, Fr8App announced a partnership with Majoba Logistics, a leading transportation company in Mexico, to increase the volume of trucks available for Fr8Fleet

For a long time, the road freight industry has had a big problem: thousands of trucks driving along interstate highways and freeways are completely empty. In fact, 35% of all miles driven by truck drivers are empty, according to a 2022 study, with this eating into the carriers’ profitability and growth (https://ibn.fm/aLMuy).

The so-called ‘deadhead’ distances result from, among others, carriers lacking two committed customers, one for the outward journey and another for the return. “But, as well as needing a shipment for the return journey, they also need a truck that matches their load, with equipment such as refrigeration or a vehicle with a fork-lift attached,” a CNBC article reads (https://ibn.fm/taEtL).

And as some observers note, the problem is also caused by the lack of coordination between shippers and carriers, meaning the proverbial willing-buyer-willing-seller rarely occurs, as both parties do not easily find each other. As a result, the outcome manifests itself in underutilized carrier assets, which negatively impacts profitability, and high prices on the part of the shippers as the carriers end up charging the empty miles to cushion against losses (https://ibn.fm/e4V8k). But there is a silver lining.

“At Fr8App, we create technology solutions that contribute to our customers’ success by improving their efficiency and profitability,” conveyed Javier Selgas, CEO of Fr8App, a subsidiary of technology company Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”), in a February 2022 news release announcing the unveiling of the Fr8Fleet product (https://ibn.fm/eMqGH). “We are thrilled to unveil our latest offering, Fr8Fleet, which matches carriers with the capacity to provide certain amounts of carriage services over time rather than on a trip-by-trip basis.”

Fr8App designed Fr8Fleet, which operates on its eponymous AI-powered freight matching platform for B2B cross-border shipping, to solve the myriad issues affecting both carriers and shippers. For instance, by enabling shippers to secure freight capacity over time, the solution helps them avoid empty-mile surcharges that may come with trip-by-trip contracts. At the same time, it guarantees participating carriers a steady stream of revenue by affording them committed capacity planning. It also allows them to track the progress of their loads. To put it simply, Fr8Fleet enables carriers to coordinate and schedule loads from different shippers, in what reduces or eliminates deadhead distances.

Since its launch, Fr8Fleet has gained traction, attracting both new and existing Fr8App clients. Most recently, Freight Technologies announced a partnership with Majoba Logistics, a leading transportation company in Mexico, to increase the volume of trucks available for Fr8Fleet. As part of the partnership, Majoba Logistics will provide high-quality and dedicated logistics services, aligning perfectly with Fr8App’s mission of revolutionizing the transportation industry (https://ibn.fm/jrHle).

The alliance, Majoba Logistics CEO Aarón Elizondo explained, is set to provide Fr8App customers additional options for their transportation needs in addition to enabling the transportation company to expand its reach and, through technology, offer safer, more efficient, and cost-effective logistics services.

“We started offering our Fr8Fleet product last year and look forward to more than doubling its size this year. We are elated to have one of the leading innovative freight companies in Mexico join our platform with the view to helping grow the traffic in our Fr8Fleet offering,” said Selgas of the alliance.

The new partnership comes a few months after the Fr8App announced receipt of a two-year commitment from Kimberly Clark de Mexico, S.A.B. de C.V. (“KCM”), a leading Mexican company in consumer products for both care and hygiene (https://ibn.fm/y0TpP). Through its commitment, KCM is set to extend a contract entered early last year, which made it the first shipper client of the Fr8Fleet product.

Fr8Tech is a technology company developing solutions to optimize and automate the supply chain process. Through Fr8App, the company has developed a b2B cross-border shipping freight matching platform that focuses on making shipping transparent and efficient by providing carriers with increased growth opportunities and shippers with flexibility, visibility, and simplicity for the once-complex process of international over-the-road (“OTR”) shipping.

For more information, visit the company’s website at www.Fr8Technologies.com.

NOTE TO INVESTORS: The latest news and updates relating to FRGT are available in the company’s newsroom at https://ibn.fm/FRGT

• Lexaria’s DehydraTECH(TM) technology has 28 granted patents, with many more patents pending worldwide
• DehydraTECH(TM) uses a patented formulation and dehydration process method to change how the body detects and absorbs drugs
• Lexaria is focusing on three main areas: CBD for hypertension, oral nicotine to replace vaping and smoking, and CBD potentially for diabetes and seizures
• Lexaria is conducting early work to support its FDA-registered IND program to investigate DehydraTECH(TM)-processed CBD for hypertension

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, is increasing the bioavailability and improving the way active pharmaceutical ingredients (“APIs”) enter the bloodstream through its patented proprietary technology, DehydraTECH(TM). DehydraTECH is applied to multiple ingestible product formats, such as tablets, capsules, oral suspensions, mouth melts, and others, with opportunities for success in cannabinoids, nicotine, antivirals, and other APIs. To date, Lexaria has 28 granted patents, with many more patents pending worldwide.

Lexaria’s DehydraTECH uses a patented formulation and dehydration processing method that changes how the body detects and absorbs drugs. The DehydraTECH process is beneficial to the end user because it speeds up onset, increases bioavailability, improves drug potency, eliminates the need for sugar-filled edibles, lowers dosage, and lowers administration costs.

In 2023, the company is focused on three main areas: cannabidiol (“CBD”) for hypertension, oral nicotine to replace vaping and smoking, and other applications for DehydraTECH-CBD such as diabetes and seizures. Lexaria has yielded several studies that have proven beneficial for its research and development efforts, including five human clinical trials completed involving DehydraTECH-CBD.

HYPER-H21-4 consisted of male and female volunteers between the ages of 40-70 with documented or measured elevated blood pressure. Participants received DehydraTECH-CBD every day for a 5-week duration, with doses escalating between 225 mg/day to 450 mg/day over the course of the study, adjusted relative to body weight. Some participants were already using the industry standard of care for hypertension, allowing Lexaria to study the efficacy and safety of DehydraTECH-CBD with and without other hypertension treatments. The extended duration of the study allowed Lexaria to gather critical data to evaluate the potential for long-term health benefits of its DehydraTECH-CBD formulation.

“Given that these were the primary objectives of the study, it is accurate to say that HYPER-H21-4 was a success,” Lexaria CEO Chris Bunka said in his annual letter to shareholders recently (https://ibn.fm/2Ewzv). “In addition, a series of secondary study objective evaluations, as previously announced, are in progress, and these findings will be released in due course if any of them are notable.”

Lexaria expects to launch its FDA-registered IND program to investigate DehydraTECH-CBD for hypertension formally. The program is a large undertaking, one that will dominate the second half of 2023 and beyond – the company expects to conduct fewer additional smaller studies than they have in years past due to the focus required for this study. Preparatory work for this Phase 1b study is well underway.

“We continue to enjoy more successes than failures. We’re hopeful that our commercial endeavors might obviate any need to raise capital via equity issuance at current market levels, and our tight fiscal controls have greatly assisted in that pursuit,” Bunka also said. He added that the company will explore various commercial arrangements in 2023 in order to increase cash flow, while also continuing efforts to build and enhance its client base.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• BiondVax Pharmaceuticals is a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products
• The company’s alpaca-derived nanosized antibodies (“NanoAbs”) exhibit superior valuable competitive advantages over commercially available monoclonal antibodies (“mAbs”), including better specificity and affinity to the target, hyper-thermostability, and potential for more effective and convenient routes of administration
• Preclinical in vivo data have shown its lead drug candidate, the inhaled anti-SARS-CoV-2 NanoAb, led to a significantly shorter and milder illness, virtually eliminated the virus from the lungs, and effectively prevented illness when administered prophylactically
• BiondVax aims to fill the void in COVID-19 therapeutics and is forging ahead with clinical efforts needed to support this goal

With the COVID-19 disease now in its fourth year, questions abound about how the pandemic will be felt in 2023. The complex interaction of the vaccinations, available therapeutic drugs, newly emerging COVID-19 drugs, and natural immunity complicates the process of determining crucial parameters that can be used to make projections surrounding disease severity and extent of the spread of the SARS-CoV-2 virus (https://ibn.fm/6f3Ng). To further compound the issue, newly emerging Omicron subvariants have rendered previously effective and approved monoclonal antibody drugs virtually ineffective, leading to the Food and Drug Administration (“FDA”)’s withdrawal of their authorization. Plus, most observers agree that the progression and evolution of the variants remain largely unpredictable three years on.

If the unpredictability and daily developments have taught us anything, it is the need for improved therapeutics. Such a therapeutic should be able to deal with both the existing and new subvariants and variants of the virus. Jerusalem-based biotechnology company, BiondVax Pharmaceuticals (NASDAQ: BVXV), and its strategic collaborators, the Max Planck Institute for Multidisciplinary Science (“MPI”) and the University Medical Center Göttingen (“UMG”), may have cracked the code, with their VHH antibodies or nanosized antibodies (“NanoAbs”) as the cryptographic key.

In addition to COVID-19, BiondVax and its collaborators aim to target indications with large unmet medical needs and growing market sizes like psoriasis, asthma, macular degeneration, and psoriatic arthritis, all diseases with known and validated antibody drug targets. According to the company, this will help shorten development timelines and lower risk. Initially, BiondVax is concentrating on COVID-19, having developed an inhaled anti-SARS-CoV-2 NanoAb candidate with potentially superior therapeutic capabilities against COVID-19.

In particular, BiondVax’s NanoAb candidate has exhibited superior affinity to its SARS-CoV-2 target, neutralizing the virus, in vitro, at drug concentrations about 100x lower than those required by previously commercially available monoclonal antibodies (“mAbs”) (https://ibn.fm/7YmGD). In a subsequent ongoing preclinical in vivo study in a standard animal model,  data has shown that the anti-COVID-19 therapy virtually eliminated the virus from the lungs (https://ibn.fm/rRM6H) and prevented illness when administered prophylactically (https://ibn.fm/jQ4Vg). It also showed that the anti-SARS-CoV-2 NanoAb led to a significantly shorter and milder illness (https://ibn.fm/k2Kqy).

Generally, NanoAbs exhibit a number of competitive advantages over mAbs. Firstly, they demonstrate superior specificity and binding affinity to the target, which can increase safety and efficacy at lower doses, allowing production at a lower cost. Secondly, they exhibit hyper-thermostability at high temperatures, potentially enabling longer shelf life and voiding the need for enhanced cold chain storage and transport.

Furthermore, their small size also enables more effective and convenient routes of administration, including inhalation. (For perspective, current mAb therapies are generally administered intravenously in a hospital setting,) And while inhaled therapeutics can be difficult to develop, BiondVax is working with industry-leading companies and organizations to develop a cost-effective, convenient, and reliable drug-device product.

According to the company, NanoAbs exhibit the potential to capture significant market share as biobetters; biobetters target the same epitope as commercially available antibodies but have improved properties. BiondVax is particularly encouraged by the high demand for COVID-19 therapeutics, demonstrated partly by the ~$18.9 billion in sales reported by Pfizer Inc. (NYSE: PFE) in 2022 for its Paxlovid drug (https://ibn.fm/iEWKn), even with the drug’s limitations of use because of serious cross-reactions with other medications and multiple other comorbidity contraindications.

Another source of encouragement is that the COVID-19 NanoAb candidate has demonstrated strong neutralization of all Omicron variants of concern (“VoC”), showing superiority over the now-deauthorized COVID-19 mAbs, which are insufficiently efficacious against Omicron and its subvariants. With the preclinical in vivo data proving highly encouraging, BiondVax plans to undertake its first-in-human clinical trial in 2023.

BiondVax Pharmaceuticals is out to prove that great things come in Nano-sized molecules and is laser focused on developing, manufacturing, and commercializing NanoAb immunotherapeutic products for the treatment of infectious diseases and large market disorders.

For more information, visit the company’s website at www.BiondVax.com.

NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV

• The International Energy Agency predicts global energy subsidies topped record high of $1 trillion in 2022, contributing to incorrect price signaling, market distortion, rising government spending, discourage renewable energy adoption
• GeoSolar develops whole home renewable energy solutions that can help insulate building owners from price shocks, contribute to energy independence
• SmartGreen(TM) Home system comprises geothermal ground loops, photovoltaic solar panels, integrated air ducts and floor loops, CERV(R) air filtration, upgrades to insulation, lighting systems, and windows
• GeoSolar plans to market SmartGreen(TM) to over 120 million homes across U.S., system can be integrated into both newly built and existing residences and commercial buildings

The International Energy Agency (“IEA”) predicts that global energy subsidies topped a record high of $1 trillion in 2022 (https://ibn.fm/mW3I9). The amount doubled from the previous year, indicating that energy markets are volatile and further contributing to global price instability. GeoSolar Technologies (“GST”), a Colorado-based climate technology company, offers SmartGreen(TM) – a whole-home renewable energy system that can help protect homeowners from price volatility while offering energy independence.

The IEA strongly supports eliminating or minimizing fossil fuel subsidies due to their adverse effects on energy markets. According to the agency, subsidies cause incorrect price signaling, market distortion, and rising government spending while discouraging renewable energy adoption. Further, the agency believes that the expansion of subsidies additionally challenges the political landscape, with Russia emerging as the most significant contributor, followed by Iran and China.

GeoSolar’s innovative technology presents a multi-pronged solution that can insulate homeowners from energy instability caused by subsidies while reducing dependence on fossil fuels. The company’s SmartGreen(TM) Home system leverages renewable energy systems and efficiency improvements to dramatically lower or even eliminate utility bills. Geothermal ground loops and photovoltaic solar panels tap into the energy of the sun and earth to generate enough power to run appliances and vehicles. Integrated air ducts and floor loops maintain an optimal temperature in any climate, and upgrades to insulation, lighting systems, and windows improve efficiency. In addition, CERV(R) air filtration provides healthy and safe indoor air quality while filtering out pollutants.

GeoSolar aims to make SmartGreen(TM) accessible and affordable through various financing options, tax deductions, and utility incentives. The company plans to market the system to over 120 million homes across the United States with options for newly built and existing residences and commercial buildings. GeoSolar is additionally conducting a Reg A+ capital raise that allows anyone to invest in GeoSolar Technologies Inc. and the SmartGreen(TM) system.

For information on GeoSolar’s Regulation A+ capital raise, visit https://www.manhattanstreetcapital.com/geosolar-technologies-inc.

For more information, visit the company’s website at www.GeoSolarPlus.com.

NOTE TO INVESTORS: The latest news and updates relating to GeoSolar Technologies are available in the company’s newsroom at https://ibn.fm/GST

• Prime Harvest recently revealed that the company’s Reg A+ equity offering has been greenlighted by the SEC
• The primary share offering will see the company market up to 10 million shares to investors at a price of $4.20 each, with estimated gross proceeds of $42 million
• The company has said that net proceeds will be destined towards the acquisition of licensed assets, continued expansion of their delivery network and general corporate purposes

Prime Harvest, a technology-focused, full-service cannabis company based in San Diego, recently announced the qualification of its equity offering under the SEC’s Regulation A+. The offering, which has officially been qualified by the U.S. Security Exchange Commission (“SEC”) as of Jan. 25, 2023, will provide the company with authorization to commence marketing its upcoming equity placement to both, accredited and non-accredited investors via its online platform, www.Weed4ThePeople.com (https://ibn.fm/yx1PM).

Prime Harvest plans to raise gross proceeds of up to $42 million through its primary share issuance, a corporate action which will see the company offer up to 10,000,000 shares of common stock for sale at an initial public offer price of $4.20 per share. The company has announced that gross proceeds from the equity raising will be destined towards the acquisition of licensed assets, the development of Prime Harvest’s direct-to-consumer application, expansion of the company’s state-wide delivery capabilities, as well as general corporate purposes.

Dating back to the company’s change in corporate strategy in 2019, a move which saw Prime Harvest transition from its origins as one of San Diego County’s founding brick and mortar cannabis outlets towards a tech-focused retailer through its Jaxx Cannabis flagship retail and delivery platform, the company has seen its prospects rise to new highs. Boasting over 60+ brand partners, Prime Harvest has seen its revenues swell by upwards of 784% between 2019-2021, a function of the company seeing its unique customer numbers rise by over 212% during that interim, with the average consumer expending $75 on average per purchase.

More recently, Prime Harvest and its retail brand, Jaxx Cannabis, have taken the sale of cannabis to new technological heights through the creation and development of the Jaxx Delivery Mobile App. A reliable, sophisticated and easy to use platform, the Jaxx Delivery App aims to expand the company’s footprint to encompass much of California’s legal market – a bold and arduous move given the rising demand from previously unexploited submarkets within the Golden State.

Prime Harvest’s actions come at a pivotal time for the US cannabis market, with over 33 US states as well as the District of Columbia currently sanctioning the legal use of some form of cannabis. Consequently, the legal cannabis industry has rapidly become one of the fastest growing sectors of the US economy, with a recent study noting that the industry accounted for 250,000 jobs as of 2020 and would likely grow to a market size of $24.1 billion by 2025 (from $6.6 billion in 2016). One study in the meantime has opined that California alone could account for a remarkable $25 billion of a projected $50 billion nationwide market by 2026.

Despite predictions on market growth being wildly divergent on the back of varying levels of optimism surrounding the industry’s development prospects, Prime Harvest has sought to pre-emptively ensure that they will be able to capitalize on the sector’s ongoing evolution through its upcoming capital raising exercise as well as its market leading retail offer via Jaxx Cannabis.

For more information, visit the company’s website at www.PrimeHarvestInc.com.

NOTE TO INVESTORS: The latest news and updates relating to Prime Harvest are available in the company’s newsroom at https://ibn.fm/PRIME

• D-Wave’s Leap(TM) cloud service will soon be available in 39 countries, including Israel, and will be accessible directly from D-Wave or AWS Marketplace
• The company is also expanding its feature selection offering, a fundamental part of machine learning, which has already shown promising results among customers in areas such as fraud detection and TV advertising optimization
• D-Wave also shared an update to its balance sheet including $20 million raised through ELOC

D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software, and services is transforming multiple industries as the world’s first commercial supplier of quantum computing solutions. D-Wave recently announced a series of product and business updates demonstrating the company’s continued progress and the momentum of its leadership in driving quantum commercialization, including a broad feature selection initiative to accelerate artificial intelligence/machine learning (AI/ML) workflows and expansion of its Leap quantum cloud service to Israel (https://ibn.fm/rnUjV).

As companies across multiple industry sectors increasingly adopt AI technology, feature selection has emerged as a key building block to help with machine learning workflows. D-Wave plans to build out its feature selection market offerings, which will span the company’s quantum hybrid solvers and professional services. It will apply its systems and services to address the growing need for finding efficient solutions to the most difficult business problems.

Feature selection is the problem of determining a small set of the most representative characteristics to improve model training and performance in machine learning. It is a critical component of machine learning and yet represents a problem that is difficult to solve through classical computers. D-Wave’s feature selection offering focuses on using quantum hybrid approaches to optimize feature selection in AI/ML model training and prediction. Based on promising work with D-Wave’s customers, the feature selection offering has demonstrated early results in areas like fraud detection and TV commercial advertising optimization. Customers can access D-Wave’s feature selection offering directly from D-Wave or AWS Marketplace (https://ibn.fm/it9Hw).

In addition to feature selection, the company also announced that the Leap quantum cloud service would soon have availability in Israel. This will allow businesses, developers, and researchers to access D-Wave’s Advantage(TM) quantum computer, hybrid quantum/classical solvers, and the integrated developer environment (“IDE”) in real-time via Leap to drive the development of business-critical, in-production hybrid applications. On March 8th, 2023, Leap will be available in 39 countries worldwide, including Israel, and will be accessible directly from D-Wave or AWS Marketplace.

“D-Wave is rapidly accelerating the commercialization of quantum computing. We’re taking a number of steps to help our customers expeditiously unlock the power of quantum computing for the enterprise today, including expanding our feature selection offerings to help solve key AI/ML workstreams, enabling access to our Advantage system in new countries, including Israel, and adopting new processes and compliance measures to reinforce our commercial-readiness,” said Alan Baratz, CEO of D-Wave.

In addition, Baratz said the company is building upon its cash position by pursuing a variety of financing options to increase access to capital and to execute on the growth opportunities ahead. Since late October 2022, D-Wave has raised approximately $20 million under the previously announced $150 million Equity Line of Credit (“ELOC”) with Lincoln Park Capital. The ELOC has been an efficient source of capital for the company during this period. The company may seek to access additional capital under the ELOC when D-Wave determines appropriate as an ongoing mechanism to fund its operations.

Baratz also said the company is expected to finance cash needs through public and/or private equity (including sales pursuant to the ELOC) and/or debt financings or other capital sources, including strategic partnerships. D-Wave reported that its current cash balance has improved since its last report in September 2022.

For more information, visit the company’s website at www.DWaveQuantum.com.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Forward-Looking Statements

This article contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which statements are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. We caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, which are subject to a number of risks. Forward-looking statements in this article include, but are not limited to, statements regarding D-Wave’s plans to build out its feature selection market offerings, the expansion of the Leap quantum cloud service to Israel, and its pursuit of, and the potential success and impact of, various financing options. We cannot assure you that the forward-looking statements in this article will prove to be accurate. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including general economic conditions and other risks; customer acceptance of our products and services; and the uncertainties and factors set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the registration statement on Form S-1 filed by the Company with the SEC on February 13, 2023, as well as factors associated with companies, such as D-Wave, that are engaged in the business of quantum computing, including anticipated trends, growth rates, and challenges in those businesses and in the markets in which they operate; the outcome of any legal proceedings that may be instituted against us; risks related to the performance of our business and the timing of expected business or financial milestones; unanticipated technological or project development challenges, including with respect to the cost and or timing thereof; the performance of our products; the effects of competition on our business; the risk that we will need to raise additional capital to execute our business plan, which may not be available on acceptable terms or at all; the risk that we may never achieve or sustain profitability; the risk that we are unable to secure or protect our intellectual property; volatility in the price of our securities; the risk that our securities will not maintain the listing on the NYSE; changes in applicable laws and regulations; the effect of pandemics, geopolitical events, natural disasters, wars, or terrorist acts on our business or the economy in general; and the impact of inflation. Furthermore, if the forward-looking statements contained in this article prove to be inaccurate, the inaccuracy may be material. In addition, you are cautioned that past performance may not be indicative of future results. In light of the significant uncertainties in these forward-looking statements, you should not place undue reliance on these statements in making an investment decision or regard these statements as a representation or warranty by any person we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this article represent our views as of the date of this article. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this article.